Rigel Pharmaceuticals, Incorporated

Theravance, Inc.

Theravance Respiratory Company, LLC

Eli Lilly and Company

Yan Chen

Rose Yen

Rajinder Paul Singh

Vanessa Taylor

Hui Li

Thilo J Heckrodt

Adam D Hughes

Kin Tso

Darren J McMurtrie

Eric L Stangeland

Mathai Mammen

John R Jacobsen

Simon Shaw

Ryan Kelley

Richard D Wilson

Melissa Fleury

Esteban Masuda

Pingyu Ding

Rao Kolluri

Jack Maung

Daniel Byun

Ihab S Darwish

Jiaxin Yu

Somasekhar Bhamidipati

Donald G Payan

Sacha Holland

Jing Zhang

Matthew Duncton

Salvador Alvarez

Zhushou Luo

Craig Husfeld

Yu-Hua Ji

Sarah Dunham

Matt Duan

Dazhong Fan

Lu Chou

Li Li

Sambaiah Thota

Ioanna Stergiades

Trevor Mischki

Tae Weon Lee

Eric Strangeland

David Sweeny

Darren Mcmurtrie

Darren John Mcmurtrie

Richard Wilson

Sambaiah Thhota

Disclosed herein are embodiments of a pyrazole compound according to formula I. Compositions comprising the compound, and a method for making the composition also are disclosed. The composition may comprise a carrier, such as a polymer and/or the composition may be a spray-dried formulation. Also disclosed is a method for using the compound and/or composition. The compound and/or composition may be useful to inhibit an IRAK protein and/or to ameliorate, treat and/or prevent an IRAK-associated disease or condition in a subject.

Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations

Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitor compounds and compositions comprising such compounds. The compounds may have a structure according to Formula I Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

Pyrimid-2-yl-pyrazole compounds as IRAK inhibitors

Disclosed herein are embodiments of a method for treating a disease or condition in a subject, comprising administering to the subject, a pyrazole compound according to formula I. The compound may be administered as a composition, such as a spray-dried formulation. The disease or condition may be hidradenitis suppurativa, or a lymphoid neoplasm, and may be chronic myeloid leukemia or chronic myelomonocytic leukemia.

Method for treating a disease or condition using a pyrazole compound or formulation thereof

Disclosed are novel benzazole compounds and compositions comprising the compounds. The compounds are useful as kinase inhibitors including interleukin receptor associated kinases (IRAK) inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

Benzazole compounds and methods for making and using the compounds

Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

IRAK inhibitors and method for making and using

Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

Amide compounds and method for making and using

Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to inhibit a RIP1 kinase in vivo or ex vivo, and also may treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.

RIP1 inhibitory compounds and methods for making and using the same

Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The compounds may have a structure according to Formula I  The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.

Heterocyclic RIP1 inhibitory compounds

Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.

Compounds within the scope of the present invention have a Formula 1 or a salt or produg thereof, where ring A is selected from cycloaliphatic; ring B is aryl; Ris selected from (C1-C10)alkyl, (C3-C10)cycloalkyl, halo, aryl, and heteroaryl; and Rand Rare independently selected from hydrogen and (C1-C6)alkyl. Disclosed compounds may have an IRAK4 ICof from 0.003 &#x3bc;M to 3.7 &#x3bc;M; a TAK1 ICof from 0.008 &#x3bc;M to 132 &#x3bc;M; and/or an IRAK4/TAK1 selectivity of from 1 to 450. Particular compounds may have an IRAK4/TAK1 selectivity of from 100 to 500. Disclosed compositions may be formulated as pharmaceutical compositions. A method for using the compounds and/or compositions also are disclosed. The method may comprise administering to a subject an effective amount of a compound within the scope of the present invention, particularly to selectively inhibit IRAK 1 and/or IRAK4 over TAK1.

2,4-diamino-pyrimidine compounds and method for making and using the compounds

Pyrazole compounds and methods for making and using the compounds

Growing community of inventors

Foster City, CA, United States of America

Yan Chen